WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Friday, November 10, 2006

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,JPAB,DWPI; PLUR=YES; OP=ADJ	
☐	L12	l1 same impoten$	1
☐	L9	l4 or L8	22
☐	L8	l1 and L7	20
☐	L7	l5 or L6	1490
☐	L6	female near3 sexual dysfunction	1380
☐	L5	female near3 arousal disorder	285
☐	L4	l1 same L2	9
☐	L3	l1 and L2	296
☐	L2	erect$ near3 (dysfunction or inabl$ or problem$ or disorder or disease)	6258
☐	L1	bFGF or basic fibroblast growth factor	12385

END OF SEARCH HISTORY

```
$%^STN;HighlightOn= ***;HighlightOff=*** ;

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1633cxq

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


********** Welcome to STN International **********

 NEWS 1       Web Page URLs for STN Seminar Schedule - N.
America
 NEWS 2       "Ask CAS" for self-help around the clock
 NEWS 3  AUG 09  INSPEC enhanced with 1898-1968 archive
 NEWS 4  AUG 28  ADISCTI Reloaded and Enhanced
 NEWS 5  AUG 30  CA(SM)/CAplus(SM) Austrian patent law
changes
 NEWS 6  SEP 11  CA/CAplus enhanced with more pre-1907
records
 NEWS 7  SEP 21  CA/CAplus fields enhanced with simultaneous
left and right
           truncation
 NEWS 8  SEP 25  CA(SM)/CAplus(SM) display of CA Lexicon
enhanced
 NEWS 9  SEP 25  CAS REGISTRY(SM) no longer includes
Concord 3D coordinates
 NEWS 10  SEP 25  CAS REGISTRY(SM) updated with amino acid
codes for pyrrolysine
 NEWS 11  SEP 28  CEABA-VTB classification code fields reloaded
with new
           classification scheme
 NEWS 12  OCT 19  LOGOFF HOLD duration extended to 120
minutes
 NEWS 13  OCT 19  E-mail format enhanced
 NEWS 14  OCT 23  Option to turn off MARPAT highlighting
enhancements available
 NEWS 15  OCT 23  CAS Registry Number crossover limit
increased to 300,000 in
           multiple databases
 NEWS 16  OCT 23  The Derwent World Patents Index suite of
databases on STN
           has been enhanced and reloaded
 NEWS 17  OCT 30  CHEMLIST enhanced with new search and
display field
 NEWS 18  NOV 03  JAPIO enhanced with IPC 8 features and
functionality
 NEWS 19  NOV 10  CA/CAplus F-Term thesaurus enhanced
 NEWS 20  NOV 10  STN Express with Discover! free maintenance
release Version
           8.01c now available

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS
VERSION IS V8.01c, CURRENT
         MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
         AND CURRENT DISCOVER FILE IS DATED 25
SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN
implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on
that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or
implementation
  of commercial gateways or other similar uses is prohibited and
may
  result in loss of user privileges and other penalties.

**********STN Columbus **********

FILE 'HOME' ENTERED AT 16:45:48 ON 10 NOV 2006

=>
=> FIL EMBASE BIOSIS CAPLUS
COST IN U.S. DOLLARS                    SINCE FILE     TOTAL
                                  ENTRY   SESSION
FULL ESTIMATED COST                        6.51      6.51

FILE 'EMBASE' ENTERED AT 17:04:32 ON 10 NOV 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 17:04:32 ON 10 NOV 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 17:04:32 ON 10 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER
AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s bFGF or basic fibroblast growth factor
L1      36990 BFGF OR BASIC FIBROBLAST GROWTH FACTOR

=> s impoten?
L2      21530 IMPOTEN?

=> s erectile (3a) (disorder or dysfunction or disease or inab?)
L3      15377 ERECTILE (3A) (DISORDER OR DYSFUNCTION OR
DISEASE OR INAB?)

=> s l2 or l3
L4      29587 L2 OR L3

=> s l1 and l4
L5        28 L1 AND L4

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6        22 DUP REM L5 (6 DUPLICATES REMOVED)

=> d bib abs 1-
YOU HAVE REQUESTED DATA FROM 22 ANSWERS -
CONTINUE? Y/(N):y

L6  ANSWER 1 OF 22  CAPLUS  COPYRIGHT 2006 ACS on STN
AN  2006:269747  CAPLUS <<LOGINID::20061110>>
DN  144:286715
TI  Thyroid hormone analogs and their polymeric conjugates, alone
or in
    combination with other drugs, as modifiers of angiogenesis
IN  Mousa, Shaker A.; Davis, Faith B.; Davis, Paul J.
PA  Ordway Research Institute, USA
SO  PCT Int. Appl., 163 pp.
    CODEN: PIXXD2
DT  Patent
LA  English
FAN.CNT 1
    PATENT NO.         KIND  DATE       APPLICATION NO.
DATE
    ---------------    ----  ---------  ------------------  --------
PI  WO 2006031922      A2    20060323   WO 2005-US32813
20050915
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY,
BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,
FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP,
KR, KZ,
            LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
MW, MX, MZ,
            NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG,
            SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN,
            YU, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB,
GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
PRAI US 2004-943072      A2  20040915
    US 2005-670534P      P   20050413
AB  Disclosed are methods of treating subjects having conditions
related to
    angiogenesis including administering an effective amt. of a
polymeric form
    of thyroid hormone, or an antagonist thereof, to promote or inhibit
    angiogenesis in the subject. Compns. of the polymeric forms of
thyroid
    hormone, or thyroid hormone analogs, are also disclosed.
Imaging agents
    are also claimed for diagnosing a neurodegenerative disease
comprising a
    labeled thyroid hormone analog that binds to transthyretin.

L6  ANSWER 2 OF 22  EMBASE  COPYRIGHT (c) 2006 Elsevier
B.V. All rights
    reserved on STN                          DUPLICATE 1
```

AN 2006186128 EMBASE <<LOGINID::20061110>>
TI Intracavernosal ***basic*** ***fibroblast*** ***growth*** ***factor*** improves vasoreactivity in the hypercholesterolemic rabbit.
AU Xie D.; Pippen A.M.; Odronic S.I.; Annex B.H.; Donatucci C.F.
CS Dr. B.H. Annex, VA Medical Center, 508 Foulton St., Durham, NC 27710, United States. annex001@mc.duke.edu
SO Journal of Sexual Medicine, (2006) Vol. 3, No. 2, pp. 223-232. .
Refs: 36
ISSN: 1743-6095 E-ISSN: 1743-6109
CY United Kingdom
DT Journal; Article
FS 003 Endocrinology
005 General Pathology and Pathological Anatomy
028 Urology and Nephrology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 8 May 2006
Last Updated on STN: 8 May 2006
AB Purpose. We determined the effects of intracavernosal injection (ICI) of recombinant ***basic*** ***fibroblast*** ***growth*** ***factor*** (rbFGF) on corporal tissue in hypercholesterolemic rabbits.
Methods. Twenty New Zealand White rabbits were fed a 1% cholesterol diet for 6 weeks and were randomly divided into four groups. Group 1 (N = 5) received an ICI of phosphate buffered saline solution (PBS) once and again 3 weeks later. Group 2 (N = 4) received an ICI of 2.5 .mu.g rbFGF once and PBS 3 weeks later. Group 3 (N = 6) received an ICI of 2.5 .mu.g rbFGF once and again 3 weeks later. Group 4 (N = 5) received an ICI of 2.5 .mu.g rbFGF once. All animals were maintained on the high cholesterol diet until sacrifice, 3 weeks after last injection. Strips of corporal tissue were submaximally contracted with norepinephrine, and dose-response curves were generated to evaluate endothelial-dependent (acetylcholine, ACH) and endothelial-independent (sodium nitroprusside, SNP) vasoreactivity. Protein levels of ***bFGF*** and vascular endothelial growth factor (VEGF) were assessed by enzyme-linked immunosorbent assay. Neuronal nitric oxide synthase (nNOS) protein and mRNA were detected by Western blot and semi-quantitative polymerase chain reaction, respectively. Results. Vasoreactivity was improved by ***bFGF*** treatment as shown by higher ED50[-log(M)] of ACH and SNP in Groups 2, 3, and 4. The expression of ***bFGF*** protein, VEGF protein, nNOS protein, and mRNA were all increased after ***bFGF*** treatment.
Conclusion. ICI of ***bFGF*** improved vasoreactivity in hypercholesterolemic rabbit corporal tissue, offering a new direction to explore for the treatment of ***erectile*** ***dysfunction*** .
.COPYRGT. 2005 International Society for Sexual Medicine.

L6 ANSWER 3 OF 22 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
AN 2006252764 EMBASE <<LOGINID::20061110>>
TI Update on ***erectile*** ***dysfunction*** in prostate cancer patients.
AU Kendirci M.; Bejma J.; Hellstrom W.J.G.
CS Dr. W.J.G. Hellstrom, Section of Andrology, Department of Urology, Tulane University Health Sciences Center, 1 430 Tulane Avenue, SL-42, New Orleans, LA 70112, United States. whellst@tulane.edu
SO Current Opinion in Urology, (2006) Vol. 16, No. 3, pp. 186-195.
Refs: 72
ISSN: 0963-0643 CODEN: CUOUEQ
PUI 000423072006050000013
CY United Kingdom
DT Journal; General Review
FS 008 Neurology and Neurosurgery
016 Cancer
028 Urology and Nephrology
030 Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 21 Jun 2006
Last Updated on STN: 21 Jun 2006
AB Purpose of review: Evolution in the management of prostate cancer includes increased attention being paid to patient quality of life after treatment, specifically with issues related to sexual function. ***Erectile*** ***dysfunction*** is one of the major concerns of patients undergoing treatment for prostate cancer. There are several recognized factors that determine the postoperative incidence of erectile difficulties, including patient age, degree of cavernosal nerve sparing during surgery, cancer stage, and associated vascular comorbidities. Early initiation of rehabilitation protocols after radical prostatectomy has been advocated to promote the speed and degree of recovery of erectile function. The aim of this communication is to review recent initiatives in ***erectile*** ***dysfunction*** restoration after prostate cancer therapy. Recent findings: In recognition of the neurogenic basis of ***erectile*** ***dysfunction*** after radical prostatectomy, new strategies have been devised to initiate the rehabilitation process. Type 5 phosphodiesterase inhibitors, vacuum erection devices, and intracavernosal and intraurethral application of vasoactive agents have all been reported in a positive light in recent studies. Developments in cavernous nerve graft interposition procedures, perioperative neuroprotection measures, and postoperative neurotrophic treatments aim to preserve prostate cancer patients' qualities of life. Summary: Data generated from a number of clinical investigations document that pharmacologic rehabilitation programs provide a higher rate of recovery of erectile function following radical prostatectomy. Both intracavernosal and intraurethral applications of vasoactive agents and vacuum devices can speed the recovery period for return of erectile function. Various neuroprotective and neurotrophic approaches are thought to provide integral roles for the maintenance of sexual function in men undergoing prostate cancer therapy.
.COPYRGT. 2006 Lippincott Williams & Wilkins.

L6 ANSWER 4 OF 22 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
AN 2006521837 EMBASE <<LOGINID::20061110>>
TI Neuromodulatory drugs for the radical prostatectomy patient: Current and future applications.
AU Webster J.C.; Davila H.H.; Parker J.; Carrion R.E.
CS Dr. R.E. Carrion, H. Lee Moffitt Cancer Center and Research Institute, Genitourinary Program, MCCC 4035, 12902 Magnolia Drive, Tampa, FL 33612-9416, United States. carriore@moffitt.usf.edu
SO Current Sexual Health Reports, (2006) Vol. 3, No. 3, pp. 120-124. .
Refs: 44
ISSN: 1548-3584 E-ISSN: 1548-3592
CY United States
DT Journal; General Review
FS 009 Surgery
016 Cancer
022 Human Genetics
028 Urology and Nephrology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 7 Nov 2006
Last Updated on STN: 7 Nov 2006
AB Prostate cancer is the most common noncutaneous malignancy in US men, with an estimated 232,000 new cases diagnosed in 2005. Radical prostatectomy (RP) has proved to be a safe and effective therapy for localized prostate cancer. However, RP can be associated with some risk of morbidity, which includes a potential compromise in erectile function. Medical therapies for ***erectile*** ***dysfunction*** after RP include vasoactive

agents and neuromodulatory agents. This review evaluates the potential
role of neuromodulatory agents in the post-RP patient. The potential of
developing an agent that has a high safety profile and long duration of
effectiveness makes these agents attractive alternatives for the future.
Copyright .COPYRGT. 2006 by Current Science Inc.

L6 ANSWER 5 OF 22 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN
AN 2006129021 EMBASE <<LOGINID::20061110>>
TI Hope springs eternal: Cavernosal nerve regeneration.
AU Syme D.B.Y.; Corcoran N.M.; Bouchier-Hayes D.M.; Costello A.J.
CS D.B.Y. Syme, Department of Urology, Royal Melbourne Hospital, Grattan St,
Parkville, Vic. 3050, Australia. david.syme@mh.org.au
SO BJU International, (2006) Vol. 97, No. 1, pp. 17-21. .
Refs: 29
ISSN: 1464-4096 E-ISSN: 1464-410X CODEN: BJINFO
CY United Kingdom
DT Journal; General Review
FS 008 Neurology and Neurosurgery
016 Cancer
021 Developmental Biology and Teratology
027 Biophysics, Bioengineering and Medical Instrumentation
028 Urology and Nephrology
LA English
ED Entered STN: 12 Apr 2006
Last Updated on STN: 12 Apr 2006
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L6 ANSWER 6 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 2006:132204 BIOSIS <<LOGINID::20061110>>
DN PREV200600144388
TI Methods and compositions for preventing and treating male ***erectile***
dysfunction and female sexual arousal disorder.
AU Lue, Tom F. [Inventor]; Lin, Ching-Shwun [Inventor]; Kan, Yuet W.
[Inventor]
CS Hillsborough, CA USA
ASSIGNEE: The Regents of the University of California
PI US 06852323 20050208
SO Official Gazette of the United States Patent and Trademark Office Patents,
(FEB 8 2005)
CODEN: OGUPE7. ISSN: 0098-1133.
DT Patent
LA English
ED Entered STN: 22 Feb 2006
Last Updated on STN: 22 Feb 2006
AB This invention relates generally to the field of urology. In particular,
the invention provides a method for preventing or treating male
erectile ***dysfunction*** or female sexual arousal disorder,
which method comprises administering an effective amount of vascular
endothelial growth factor (VEGF), brain-derived neurotrophic factor
(BDNF), ***basic*** ***fibroblast*** ***growth***
factor (***bFGF***), or a functional derivative or fragment
thereof, or a nucleic acid encoding said VEGF, BDNF or ***bFGF*** , or
functional derivative or fragment thereof, or an agent that enhances
production and/or erection or sexual arousal stimulating function of said
VEGF or BDNF or ***bFGF*** to a mammal, wherein such prevention or
treatment is desirable, thereby preventing or treating said male
erectile ***dysfunction*** or female sexual arousal disorder
in said mammal. Combinations, combinatorial methods and kits for
preventing or treating male ***erectile*** ***dysfunction*** or
female sexual arousal disorder are also provided. STATEMENT OF RIGHTS TO
INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH This invention is
supported by Grant No. DK45370 and DK51374 of the National Institutes of
Health. The United States government may have certain rights in this
invention. The disclosure of the above-described application is
incorporated herein by reference in its entirety.

L6 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:283330 CAPLUS <<LOGINID::20061110>>
DN 142:330277
TI Thyroid hormone analogs and their polymeric conjugates, alone or in
combination with other drugs, as modifiers of angiogenesis
IN Mousa, Shaker A.; Davis, Faith B.; Davis, Paul J.
PA Ordway Research Institute, USA
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005027895	A2	20050331	WO 2004-US30583	20040915
WO 2005027895	A3	20050506		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

AU 2004273986	A1	20050331	AU 2004-273986	20040915
CA 2539288	AA	20050331	CA 2004-2539288	20040915
EP 1670449	A2	20060621	EP 2004-784443	20040915

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRAI US 2003-502721P	P	20030915
WO 2004-US30583	W	20040915

AB Disclosed are methods of treating subjects having conditions related to
angiogenesis including administering an effective amt. of a polymeric form
of thyroid hormone, or an antagonist thereof, to promote or inhibit
angiogenesis in the subject. Compns. of the polymeric forms of thyroid
hormone, or thyroid hormone analogs, are also disclosed.

L6 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1132649 CAPLUS <<LOGINID::20061110>>
DN 143:411065
TI Drug delivery systems containing drugs in a water soluble composition
immersed in a hydrophobic medium for improved penetration through
biological barriers
IN Ben-Sasson, Shmuel A.
PA Israel
SO U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005232981	A1	20051020	US 2005-105763	20050414
WO 2006097793	A2	20060921	WO 2005-IB4183	20050414

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,

SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM
PRAI US 2004-562345P P 20040415
OS MARPAT 143:411065
AB This invention relates to novel penetrating compns. including one or more
effectors included within a water sol. compn., immersed in a hydrophobic
medium. The invention also relates to methods of treating or preventing
diseases by administering such penetrating compns. to affected subjects.
For example, a compn. with improved insulin across epithelial barrier
contained insulin, spermine, phytic acid, sodium dodecanoate,
octanol/geraniol, mineral oil/medium chain triglycerides/castor oils.

L6 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:546880 CAPLUS <<LOGINID::20061110>>
DN 143:83457
TI compositions facilitating translocation of therapeutic effector across
biol. barrier comprising hydrophobic agent, counter ion, penetrating
peptide, and/or protease inhibitor
IN Ben-Sasson, Shmuel A.; Cohen, Einat
PA Israel
SO U.S. Pat. Appl. Publ., 59 pp., Cont.-in-part of U.S. Ser. No. 665,184.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005136103	A1	20050623	US 2004-942300	20040916
US 2004146549	A1	20040729	US 2003-665184	20030917
US 7115707	B2	20061003		
US 2005058702	A1	20050317	US 2003-664989	20030917
PRAI US 2003-503615P	P	20030917		
US 2003-664989	A2	20030917		
US 2003-665184	A2	20030917		
US 2002-355396P	P	20020207		
WO 2003-IB968	A2	20030207		

OS MARPAT 143:83457
AB This invention relates to novel pharmaceutical compns. capable of
facilitating penetration of at least one effector across biol. barriers.
The compns. may comprise therapeutic effectors, hydrophobic agents,
counter ions, protein stabilizers, penetrating peptides, surface active
agents, and protease inhibitors. Disclosed are methods for producing the
compns. of the invention, and their uses. The invention also relates to
methods of treating or preventing diseases by administering these compns.
to affected subjects, and methods of vaccination.

L6 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:238432 CAPLUS <<LOGINID::20061110>>
DN 142:303641
TI Compositions capable of facilitating penetration across a biological
barrier
IN Ben-Sasson, Shmuel A.; Cohen, Einat
PA Israel
SO U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005058702	A1	20050317	US 2003-664989	20030917
US 2005136103	A1	20050623	US 2004-942300	20040916
AU 2004317954	A1	20051013	AU 2004-317954	20040917
CA 2539043	AA	20051013	CA 2004-2539043	20040917
WO 2005094785	A2	20051013	WO 2004-IB4452	20040917
WO 2005094785	A3	20060323		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP 1670500	A2	20060621	EP 2004-821561	20040917

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRAI US 2003-503615P	P	20030917
US 2003-664989	A2	20030917
US 2003-665184	A2	20030917
WO 2004-IB4452	W	20040917

AB This invention relates to novel pharmaceutical compns. for delivery of
biol. active mols., such as polypeptides, drugs and other therapeutic
agents, across various biol. barriers mixing one or more effectors
(anionic impermeable mols.) with a counter ion to the effector (a liq.
forming cation). The invention also relates to methods of treating or
preventing diseases by administering pharmaceutical compns. to affected
subjects. For example, an ionic liq. forming cation was used to enable
the translocation of insulin across an epithelial barrier. A compn.
contg. recombinant human insulin and an ionic liq. forming cation, e.g.,
1-butyl-3-methylimidazolium chloride, together with phytic acid, Pluronic
F68, aprotinin, Solutol HS-15, and N-acetylcysteine was administrated
rectally or by injection into an intestinal loop of a test animal, e.g., a
mouse. Blood glucose levels decrease in relation to the amt. of insulin
absorbed from the intestine into the bloodstream (i.e., in an amt. that
correlates to the amt. of insulin absorbed). Thus, this drug delivery
system can replace the need for insulin injections, thereby providing an
efficient, safe and convenient route of administration for diabetes
patients.

L6 ANSWER 11 OF 22 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN DUPLICATE 2
AN 2005128060 EMBASE <<LOGINID::20061110>>
TI Effect of ***basic*** ***fibroblast*** ***growth***
factor incorporating gelatin microspheres on erectile function in
the diabetic rat.
AU Suetomi T.; Hisasue S.-I.; Sato Y.; Tabata Y.; Akaza H.; Tsukamoto T.
CS S.-I. Hisasue, Department of Urology, Sapporo Medical University, School
of Medicine, S1-W16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan.
hisasue@sapmed.ac.jp
SO Journal of Urology, (2005) Vol. 173, No. 4, pp. 1423-1428. .
Refs: 20
ISSN: 0022-5347 CODEN: JOURAA

CY United States
DT Journal; Article
FS 003 Endocrinology
028 Urology and Nephrology
029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 7 Apr 2005
Last Updated on STN: 7 Apr 2005
AB Purpose: We report the potential of ***basic*** ***fibroblast***
growth ***factor*** (***bFGF***) incorporating gelatin microspheres to preserve erectile function in a diabetic rat model. Materials and Methods: A total of 48 adult male rats were divided into 3 groups, namely control (nondiabetic rats), diabetes mellitus (DM) (diabetic rats that received gelatin microspheres with saline) and ***bFGF*** (diabetic rats that received gelatin microspheres with ***bFGF***). After 4 and 8 weeks we examined intracavernous pressure responses with electrical stimulation to the cavernous nerve. For histological examination of the penis we performed Azan-Mallory staining for smooth muscle and collagen, and immunohistochemistry for endothelial nitric oxide synthase (NOS) in endothelium and neuronal NOS in cavernous nerve fiber. Results: Although the intracavernous pressure response was significantly lower in the DM group than in the control group, pressure in the ***bFGF*** group was maintained at the normal level found in controls. Azan-Mallory staining showed a mass decrease in smooth muscle in cavernous tissue in the DM group. However, that in the ***bFGF*** group was maintained. There was no significant difference in endothelial NOS positive areas and the distribution of the diameter of neuronal NOS positive nerve fibers in cavernous tissue among the 3 groups. Conclusions: We report the maintenance of erectile function with ***bFGF*** incorporating gelatin microspheres in diabetic rats. The rationale of this maneuver is smooth muscle preservation by the long-term release of ***bFGF*** . This is a novel therapeutic option that is clinically applicable for diabetes induced ***erectile*** ***dysfunction*** . Copyright .COPYRGT. 2005 by American Urological Association.

L6 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:20807 CAPLUS <<LOGINID::20061110>>
DN 140:99589
TI Use of peptides derived from junctional adhesion molecules to permeabilize mucosa for improved efficiency of mucosal delivery of therapeutic compounds
IN Quay, Steven C.
PA Nastech Pharmaceutical Company, Inc., USA
SO PCT Int. Appl., 426 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004003145	A2	20040108	WO 2003-US19994	20030624
WO 2004003145	A3	20040610		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2487712	AA	20040108	CA 2003-2487712	20030624
AU 2003279750	A1	20040119	AU 2003-279750	20030624
US 2004077540	A1	20040422	US 2003-601953	20030624
EP 1539208	A2	20050615	EP 2003-742185	20030624

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005537244	T2	20051208	JP 2004-517800	20030624
ZA 2004010287	A	20051118	ZA 2004-10287	20041221

PRAI US 2002-392512P P 20020628
WO 2003-US19994 W 20030624
AB Methods of improving the permeability of mucosal epithelia to improve the efficiency of transmucosal delivery of drugs are described. Permeability is improved by modulating epithelial junction structure or physiol. of the mucosa using a peptide derived from one of the proteins involved in the junction, such as junctional adhesion mols. (JAMs), occludins, or claudins. The permeabilizing agent is typically a peptide or peptide analog or mimetic, often selected or derived from an extracellular domain of a mammalian JAM, occludin or claudin protein. Identification of candidate peptides derived from junctional adhesion mol. JAM-1, claudins and occludins is demonstrated. The effects of the peptides were tested in a com. airway epithelium model. Tests in adult male volunteers showed a significant improvement in the delivery of human interferon .beta. across the nasal mucosa when a peptide derived from JAM-1 was included in an intranasal formulation.

L6 ANSWER 13 OF 22 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
AN 2004360286 EMBASE <<LOGINID::20061110>>
TI Anagrelide: A decade of clinical experience with its use for the treatment of primary thrombocythaemia.
AU Petrides P.E.
CS Dr. P.E. Petrides, Department of Medicine, University of Munich Medical School, Hematology Oncology Center, Zweibbruckenstr. 2, 80331 Munich, Germany. Petrides@onkologiemuenchen.de
SO Expert Opinion on Pharmacotherapy, (2004) Vol. 5, No. 8, pp. 1781-1798. .
Refs: 132
ISSN: 1465-6566 CODEN: EOPHF7
CY United Kingdom
DT Journal; General Review
FS 025 Hematology
030 Pharmacology
036 Health Policy, Economics and Management
037 Drug Literature Index
038 Adverse Reactions Titles
039 Pharmacy
LA English
SL English
ED Entered STN: 9 Sep 2004
Last Updated on STN: 9 Sep 2004
AB Primary thrombocythaemia (PT) is the most frequent among the rare chronic myeloproliferative disorders. Life expectancy is determined by thromboembolic and haemorrhagic complications, which can be prevented by cytoreductive therapy. For a long time, hydroxyurea has been considered as the therapeutic gold standard. However, hydroxyurea treatment is not lineage-specific, may not be tolerated because of adverse effects (skin, gastrointestinal tract) and is leukaemogenic when sequentially used with

other DNA-targeting drugs. Hence, anagrelide was welcomed in 1988 when it
was first described as being efficient at normalising elevated platelet
counts, specific for megakaryocytes and non-mutagenic. Since then,
anagrelide has been approved in the US and Canada (Agrylin.RTM., Shire
Pharmaceuticals) as well as in Austria and other countries of the EU
(Thromboreductin.RTM., AOP Orphan Pharmaceuticals). Clinical Phase III
trials (PT1 and ANAHYDRET) are underway to directly compare the efficacy
and safety of anagrelide and hydroxyurea. .COPYRGT. 2004 Ashley
Publications Ltd.

L6 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:396441 CAPLUS <<LOGINID::20061110>>
DN 138:396636
TI Methods and compositions for preventing and treating male ***erectile***
dysfunction and female sexual arousal disorder
IN Lue, Tom F.; Lin, Ching-shwun; Kan, Yuet W.; Carroll, Peter
PA USA
SO U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 909,544.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003096747	A1	20030522	US 2002-155785	20020523
US 2002160951	A1	20021031	US 2001-909544	20010719
US 6852323	B2	20050208		
US 2004180830	A1	20040916	US 2004-806515	20040322
US 2005233962	A1	20051020	US 2005-40947	20050121

PRAI US 2000-220031P P 20000721
US 2001-909544 A2 20010719
US 2002-155785 A3 20020523
AB The invention provides a method for preventing or treating male ***erectile*** ***dysfunction*** or female sexual arousal disorder
by administering an effective amt. of one or more factors from a group of
factors including vascular endothelial growth factor, brain-derived neurotrophic factor, ***basic*** ***fibroblast*** ***growth*** ***factor*** , neurotrophin-3, neurotrophin-4, or angiopoietin-1, wherein
the factor is a full length protein or a nucleic acid encoding the factor,
or a functional deriv. or fragment thereof, or an agent that enhances
prodn. and/or male erection or female sexual arousal stimulating function
of the factor(s). Combinations, kits, and combinatorial methods are also
provided. Also claimed is a method to identify compds. promoting growth
of cavernous nerves from major pelvic ganglia.

L6 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:334645 CAPLUS <<LOGINID::20061110>>
DN 138:348752
TI Sense mRNA therapy using stabilized mRNA
IN Wiederholt, Kristin; Woolf, Tod M.; Taylor, Margaret
PA Lahive & Cockfield, LLP, USA
SO U.S. Pat. Appl. Publ., 23 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003083272	A1	20030501	US 1998-156323	19980918

PRAI US 1997-59371P P 19970919
AB The invention describes methods for the stabilization of mRNA. These
alterations increase stability of mRNA and enable its use in sense RNA
therapy to transiently express proteins in a cell. Methods are provided
for making such modifications, as are compns. comprising such modifications, and the use of such compns. in treating disease states.

L6 ANSWER 16 OF 22 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN DUPLICATE 3
AN 2003292152 EMBASE <<LOGINID::20061110>>
TI Systemic ***basic*** ***fibroblast*** ***growth*** ***factor*** induces favorable histological changes in the corpus
cavernosum of hypercholesterolemic rabbits.
AU Dai Q.; Silverstein A.D.; Davies M.G.; Hagen P.-O.; Donatucci C.F.; Annex
B.H.
CS B.H. Annex, Division of Cardiology, Durham Vet. Aff./Duke Univ. Med. C.,
Box 111A, 508 Fulton St., Durham, NC 27710, United States
SO Journal of Urology, (1 Aug 2003) Vol. 170, No. 2 I, pp. 664-668. .
Refs: 20
ISSN: 0022-5347 CODEN: JOURAA
CY United States
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
018 Cardiovascular Diseases and Cardiovascular Surgery
028 Urology and Nephrology
030 Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 10 Aug 2003
Last Updated on STN: 10 Aug 2003
AB Purpose: Hypercholesterolemia causes ***erectile*** ***dysfunction*** that is associated with abnormalities in vascular
smooth muscle and endothelial cells. We determined the effects of
basic ***fibroblast*** ***growth*** ***factor*** (***bFGF***) on corporeal tissue in hypercholesterolemic rabbits.
Materials and Methods: A total of 16 New Zealand White rabbits were fed a
1% cholesterol diet for 6 weeks and were randomly divided into 3 groups.
Group 1 (5 rabbits) received 2.5 .mu.g recombinant ***bFGF*** intravenously once and again 3 weeks later. Group 2 (6 rabbits) received
2.5 .mu.g ***bFGF*** intravenously once and placebo 3 weeks later.
Group 3 (5 rabbits) received placebo intravenously each time. Rabbits
were continuously fed a 1% cholesterol diet and sacrificed 3 weeks after
the last treatment. Smooth muscle, endothelial cell and collagen content
were assessed by immunohistochemistry and histochemical staining of
corporeal tissue. Vascular endothelial growth factor (VEGF) protein and
mRNA expression were assessed by enzyme-linked immunosorbent assay and
reverse transcriptase-polymerase chain reaction. Results: Corporeal
smooth muscle content was greater in groups 1 and 2 (35.24% .+. 4.25% and
24.79% .+. 3.39%, p <0.01) vs group 3 (19.68% .+. 2.94%, vs groups 1 and
2 p <0.001 and <0.05, respectively). Endothelial cell and collagen
content were similar among the groups. VEGF protein was increased in
group 1 vs group 2 (97.90 .+. 26.00 vs 57.03 .+. 14.99 pg/ml, p <0.01)
and vs group 3 (39.93 .+. 15.08, p <0.01). There was no statistical
difference between groups 2 and 3. VEGF mRNA expression was similar among
the groups. Conclusions: Systemic ***bFGF*** increases smooth muscle
content and VEGF protein in hypercholesterolemic rabbit corporeal tissue.

L6 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:89855 CAPLUS <<LOGINID::20061110>>
DN 136:129429
TI Methods and compositions for preventing and treating male ***erectile***
dysfunction and female sexual arousal disorder using VEGF, BDNF,
or ***bFGF***
IN Lue, Tom F.; Lin, Ching-Shwun; Kan, Yuet W.

PA USA
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2002007757 A2 20020131 WO 2001-US22970 20010719
WO 2002007757 A3 20030918
WO 2002007757 C2 20040506
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG
EP 1365794 A2 20031203 EP 2001-957212 20010719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI US 2000-220031P P 20000721
WO 2001-US22970 W 20010719
AB This invention relates generally to the field of urol. In particular, the
invention provides a method for preventing or treating male ***erectile*** ***dysfunction*** or female sexual arousal disorder,
which method comprises administering an effective amt. of vascular
endothelial growth factor (VEGF), brain-derived neurotrophic factor
(BDNF), ***basic*** ***fibroblast*** ***growth*** ***factor*** (***bFGF***), or a functional deriv. or fragment
thereof, or a nucleic acid encoding said VEGF, BDNF or ***bFGF*** , or
functional deriv. or fragment thereof, or an agent that enhances prodn.
and/or erection or sexual arousal stimulating function of said VEGF or
BDNF or ***bFGF*** to a mammal, wherein such prevention or treatment
is desirable, thereby preventing or treating said male ***erectile***
dysfunction of female sexual arousal disorder in said mammal.
Combinations, combinatorial methods and kits for preventing or treating
male ***erectile*** ***dysfunction*** or female sexual arousal
disorder are also provided.

L6 ANSWER 18 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN
AN 2002:422159 BIOSIS <<LOGINID::20061110>>
DN PREV200200422159
TI Nitric oxide synthase and angiogenic growth factor expressions in the
penis of an animal model of type 2 diabetes.
AU Jesmin, Subrina [Reprint author]; Sakuma, Ichiro [Reprint author];
Hattori, Yuichi; Kitabatake, Akira [Reprint author]
CS Department of Cardiovascular Medicine, Hokkaido University Graduate School
of Medicine, Sapporo, 060-8638, Japan
SO Nitric Oxide, (June, 2002) Vol. 6, No. 4, pp. 406. print.
Meeting Info.: Second International Conference on Biology, Chemistry and
Therapeutic Applications. Prague, Czech Republic. June 16-20, 2002.
ISSN: 1089-8603.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 7 Aug 2002
Last Updated on STN: 7 Aug 2002

L6 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:265259 CAPLUS <<LOGINID::20061110>>
DN 134:276162
TI Method of treating ***erectile*** ***dysfunction*** by administering an angiogenic growth factor such as VEGF or active fragment
or mimetic thereof
IN Donatucci, Craig; Miller, Julie M.
PA Duke University, USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2001024809 A1 20010412 WO 2000-US26782 20000929
W: AU, CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE
CA 2386480 AA 20010412 CA 2000-2386480 20000929
EP 1223957 A1 20020724 EP 2000-967083 20000929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY
US 2004033944 A1 20040219 US 2002-315248 20021210
PRAI US 1999-157053P P 19991001
US 2000-675659 B1 20000929
WO 2000-US26782 W 20000929
AB The present invention relates, in general, to ***erectile*** ***dysfunction*** and, in particular, to a method of treating or preventing dysfunction of penile, clitoral or vaginal erectile tissue by
administering an angiogenic growth factor, such as vascular endothelial
growth factor (VEGF), or active fragment thereof or mimetic thereof.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:167844 CAPLUS <<LOGINID::20061110>>
DN 134:227368
TI Nitric oxide-producing polymeric hydrogel materials
IN Hill-West, Jennifer L.; Bohl, Kristyn Simcha
PA Rice University, USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2001015738 A2 20010308 WO 2000-US24058 20000901
WO 2001015738 A3 20020131
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2353531 AA 20010308 CA 2000-2353531 20000901
EP 1194171 A2 20020410 EP 2000-959750 20000901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE,
SI, LT, LV, FI, RO
PRAI US 1999-152054P P 19990902
WO 2000-US24058 W 20000901
AB Hydrogels releasing or producing NO, most preferably photopolymerizable

biodegradable hydrogels capable of releasing physiol. amts. of NO for prolonged periods of time, are applied to sites on or in a patient in need of treatment thereof for disorders such as restenosis, thrombosis, asthma, wound healing, arthritis, penile ***erectile*** ***dysfunction*** or other conditions where NO plays a significant role. The hydrogels are typically formed of macromers, which preferably include biodegradable regions, and have bound thereto groups that are released in situ to elevate or otherwise modulate NO levels at the site where treatment is needed. The macromers can form a homo or hetero-dispersion or soln., which is polymd. to form a hydrogel material, that in the latter case can be a semi-interpenetrating network or interpenetrating network. Compds. to be released can be phys. entrapped, covalently or ionically bound to macromer, or actually form a part of the polymeric material. The hydrogel can be formed by ionic and/or covalent crosslinking. Other active agents, including therapeutic, prophylactic, or diagnostic agents, can also be included within the polymeric material.

L6 ANSWER 21 OF 22 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 4
AN 2000371347 EMBASE <<LOGINID::20061110>>
TI Effect of a Chinese herbal medicine mixture on a rat model of hypercholesterolemic ***erectile*** ***dysfunction*** .
AU Bakircioglu M.E.; Hsu K.; El-Sakka A.; Sievert K.-D.; Lin C.S.; Lue T.F.
CS T.F. Lue, Department of Urology, University of California, San Francisco, CA 94143, United States
SO Journal of Urology, (2000) Vol. 164, No. 5, pp. 1798-1801. . Refs: 12
ISSN: 0022-5347 CODEN: JOURAA
CY United States
DT Journal; Article
FS 028 Urology and Nephrology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 16 Nov 2000
Last Updated on STN: 16 Nov 2000
AB Purpose: We examine the effect of a Chinese herbal medicine mixture on erectile function in a rat model of hypercholesterolemic ***erectile*** ***dysfunction*** . Materials and Methods: In this study 32, 3-month-old Sprague-Dawley rats were used. The 8 control animals were fed a normal diet and the remaining 24 were fed 1% cholesterol diet for 4 months. After 2 months herbal medicine was added to the drinking water of the treatment group of 16 rats but not the cholesterol only group of 8. Of the 16 rats 8 received 25 mg./kg. per day (group 1) and 8 received 50 mg./kg. per day (group 2) of Chinese herbal medicine mixture. Serum cholesterol levels were measured at 2 and 4 months. At 4 months erectile function was evaluated with cavernous nerve electrostimulation in all animals. Penile tissues were collected for electron microscopy, and to perform Western blot for endothelial nitric oxide synthase, neuronal nitric oxide synthase, ***basic*** ***fibroblast*** ***growth*** ***factor*** (***bFGF***) and caveolin-1. Results: Serum cholesterol levels were significantly higher in animals fed the 1% cholesterol diet compared to controls at 2 and 4 months. Nevertheless, there was no significant difference among group 1 (145 .+. 30 mg./dl.), group 2 (157 .+. 20) and the cholesterol only group (143 .+. 15). Systemic arterial pressure was not significantly different between the animals that were fed the 1% cholesterol diet and the controls. During electrostimulation of the cavernous nerve peak sustained intracavernous pressure was significantly lower in the cholesterol only group (50 .+. 23 cm. H2O) compared to the control group. Conversely erectile function was not impaired in the herbal medicine treated rats. Electron microscopy showed many caveolae with fingerlike processes in the cavernous smooth muscle and endothelial cell membranes in control and treated rats but not in the cholesterol only group of rats. Western blot did not show a difference among groups in protein expression for endothelial nitric oxide synthase and neuronal nitric oxide synthase in penile tissue but caveolin-1 and ***bFGF*** protein expression was significantly higher in groups 1 and 2 than in the cholesterol only and control groups. Conclusions: Rats developed ***erectile*** ***dysfunction*** after being fed a 1% cholesterol diet for 4 months. Although serum cholesterol levels were similar in the cholesterol only rats and those treated with Chinese herbal medicine mixture, erectile response was significantly better in the treated group. The mechanism of the herbal medicine is unknown. High levels of ***bFGF*** and caveolin-1 expression in the treated group may protect the cavernous smooth muscle and endothelial cells from the harmful effect of high serum cholesterol.

L6 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:722933 CAPLUS <<LOGINID::20061110>>
DN 131:332126
TI Muscle-derived cell mediated gene delivery for treating muscle- and bone-related injury or dysfunction
IN Chancellor, Michael B.; Huard, Johnny
PA University of Pittsburgh, USA
SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9956785	A2	19991111	WO 1999-US9451	19990430
WO 9956785	A3	20010419		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2330660	AA	19991111	CA 1999-2330660	19990430
AU 9937757	A1	19991123	AU 1999-37757	19990430
EP 1113807	A2	20010711	EP 1999-920202	19990430
R: AT, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6866842	B1	20050315	US 1999-302896	19990430
EP 1604674	A2	20051214	EP 2005-57	19990430
EP 1604674	A3	20051221		
R: AT, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 2005265978	A1	20051201	US 2005-40900	20050121
PRAI US 1998-83917P	P	19980501		
EP 1999-920202	A3	19990430		
US 1999-302896	A3	19990430		
WO 1999-US9451	W	19990430		

AB The invention provides muscle-derived cells, preferably myoblasts and

muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting prodn. of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, ***basic*** ***fibroblast*** ***growth*** ***factor*** , epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-.beta., transforming growth factor-.alpha., nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.

=> s female (3a) (sexual disorder or arousal dysfunction)
L7 41 FEMALE (3A) (SEXUAL DISORDER OR AROUSAL DYSFUNCTION)

=> s hia
L8 940 HIA

=> d his

(FILE 'HOME' ENTERED AT 16:45:48 ON 10 NOV 2006)

FILE 'EMBASE, BIOSIS, CAPLUS' ENTERED AT 17:04:32 ON 10 NOV 2006
L1 36990 S BFGF OR BASIC FIBROBLAST GROWTH FACTOR
L2 21530 S IMPOTEN?
L3 15377 S ERECTILE (3A) (DISORDER OR DYSFUNCTION OR DISEASE OR INAB?)
L4 29587 S L2 OR L3
L5 28 S L1 AND L4
L6 22 DUP REM L5 (6 DUPLICATES REMOVED)
L7 41 S FEMALE (3A) (SEXUAL DISORDER OR AROUSAL DYSFUNCTION)
L8 940 S HIA

=> s l1 and l7
L9 0 L1 AND L7

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	104.98	111.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.00	-9.00

STN INTERNATIONAL LOGOFF AT 17:11:10 ON 10 NOV 2006